id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-2271-0006,FDA,FDA-2019-E-2271,"Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940",Notice,Determinations,2022-11-14T05:00:00Z,2022,11,2022-11-14T05:00:00Z,2023-01-14T04:59:59Z,2022-11-14T16:28:59Z,2022-24719,0,0,09000064854aac1b
FDA-2019-E-2271-0005,FDA,FDA-2019-E-2271,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T16:20:47Z,,0,0,09000064852ce342
FDA-2019-E-2271-0004,FDA,FDA-2019-E-2271,Letter from Office of Patent Legal Administration/ Office of the Deputy Commissioner for Patents to FDA CDER,Other,Letter(s),2022-05-27T04:00:00Z,2022,5,2022-05-27T04:00:00Z,,2022-05-27T18:09:00Z,,0,0,0900006485100826